» Articles » PMID: 37337301

Single-cell Transcriptome Profiling of Sepsis Identifies HLA-DRS100A Monocytes with Immunosuppressive Function

Abstract

Background: Sustained yet intractable immunosuppression is commonly observed in septic patients, resulting in aggravated clinical outcomes. However, due to the substantial heterogeneity within septic patients, precise indicators in deciphering clinical trajectories and immunological alterations for septic patients remain largely lacking.

Methods: We adopted cross-species, single-cell RNA sequencing (scRNA-seq) analysis based on two published datasets containing circulating immune cell profile of septic patients as well as immune cell atlas of murine model of sepsis. Flow cytometry, laser scanning confocal microscopy (LSCM) imaging and Western blotting were applied to identify the presence of S100A9 monocytes at protein level. To interrogate the immunosuppressive function of this subset, splenic monocytes isolated from septic wild-type or S100a9 mice were co-cultured with naïve CD4 T cells, followed by proliferative assay. Pharmacological inhibition of S100A9 was implemented using Paquinimod via oral gavage.

Results: ScRNA-seq analysis of human sepsis revealed substantial heterogeneity in monocyte compartments following the onset of sepsis, for which distinct monocyte subsets were enriched in disparate subclusters of septic patients. We identified a unique monocyte subset characterized by high expression of S100A family genes and low expression of human leukocyte antigen DR (HLA-DR), which were prominently enriched in septic patients and might exert immunosuppressive function. By combining single-cell transcriptomics of murine model of sepsis with in vivo experiments, we uncovered a similar subtype of monocyte significantly associated with late sepsis and immunocompromised status of septic mice, corresponding to HLA-DRS100A monocytes in human sepsis. Moreover, we found that S100A9 monocytes exhibited profound immunosuppressive function on CD4 T cell immune response and blockade of S100A9 using Paquinimod could partially reverse sepsis-induced immunosuppression.

Conclusions: This study identifies HLA-DRS100A monocytes correlated with immunosuppressive state upon septic challenge, inhibition of which can markedly mitigate sepsis-induced immune depression, thereby providing a novel therapeutic strategy for the management of sepsis.

Citing Articles

Identification of diagnostic biomarkers related to the efferocytosis pathway and immune cell infiltration characteristics in pediatric sepsis by bioinformatics analysis.

Guo L, Wang Y, Qiu X, Su W, Chen Y, Chen Y Medicine (Baltimore). 2025; 104(6):e41267.

PMID: 39928821 PMC: 11813005. DOI: 10.1097/MD.0000000000041267.


Causal relationship between cancer and immune cell traits: A two-sample mendelian randomization study.

Qiu Z, Fan J, He J, Huang X, Yang Z, Sheng Q Heliyon. 2024; 10(21):e39732.

PMID: 39583800 PMC: 11582454. DOI: 10.1016/j.heliyon.2024.e39732.


Personalized, disease-stage specific, rapid identification of immunosuppression in sepsis.

Pappa T, Rivas A, Iandiorio M, Hoogesteijn A, Fair J, Gil A Front Immunol. 2024; 15:1430972.

PMID: 39539549 PMC: 11558526. DOI: 10.3389/fimmu.2024.1430972.


Single cell RNA-seq reveals cellular and transcriptional heterogeneity in the splenic CD11bLy6C monocyte population expanded in sepsis-surviving mice.

Watanabe H, Rana M, Son M, Chiu P, Fei-Bloom Y, Choi K Mol Med. 2024; 30(1):202.

PMID: 39506629 PMC: 11539566. DOI: 10.1186/s10020-024-00970-0.


A protocol to isolate and characterize pure monocytes and generate monocyte-derived dendritic cells through FBS-Coated flasks.

Meskini M, Amanzadeh A, Salehi F, Bouzari S, Karimipoor M, Fuso A Sci Rep. 2024; 14(1):23956.

PMID: 39397067 PMC: 11471755. DOI: 10.1038/s41598-024-75376-3.


References
1.
Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

2.
Rudd K, Johnson S, Agesa K, Shackelford K, Tsoi D, Kievlan D . Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020; 395(10219):200-211. PMC: 6970225. DOI: 10.1016/S0140-6736(19)32989-7. View

3.
Reinhart K, Daniels R, Kissoon N, Machado F, Schachter R, Finfer S . Recognizing Sepsis as a Global Health Priority - A WHO Resolution. N Engl J Med. 2017; 377(5):414-417. DOI: 10.1056/NEJMp1707170. View

4.
Torres L, Pickkers P, van der Poll T . Sepsis-Induced Immunosuppression. Annu Rev Physiol. 2021; 84:157-181. DOI: 10.1146/annurev-physiol-061121-040214. View

5.
Marshall J . Why have clinical trials in sepsis failed?. Trends Mol Med. 2014; 20(4):195-203. DOI: 10.1016/j.molmed.2014.01.007. View